TipRanks

Notifications

Tag: EXAS

Total 185 Posts

Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXASResearch Report) and Geron (GERNResearch Report) with bullish sentiments.

Exact Sciences (EXAS)

In a report issued on March 14, Puneet Souda from Leerink Partners maintained a Buy rating on Exact Sciences. The company’s shares closed last Monday at $58.86, close to its 52-week low of $56.05.

According to TipRanks.com, Souda is ranked 0 out of 5 stars with an average return of -8.4% and a 38.5% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exact Sciences with a $89.00 average price target, representing a 52.9% upside. In a report issued on March 14, Canaccord Genuity also maintained a Buy rating on the stock with a $90.00 price target.

See today’s best-performing stocks on TipRanks >>

Geron (GERN)

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Geron on March 14 and set a price target of $4.50. The company’s shares closed last Monday at $3.18.

According to TipRanks.com, Beatty is a 5-star analyst with an average return of 11.6% and a 47.7% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Intra-Cellular Therapies, and ACADIA Pharmaceuticals.

Geron has an analyst consensus of Strong Buy, with a price target consensus of $5.08, which is a 51.6% upside from current levels. In a report issued on February 28, Needham also maintained a Buy rating on the stock with a $4.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EXAS: